News & Updates

In a cohort of veterans with COVID-19, former smokers are at higher risk of 30-day mortality compared with current smokers and nonsmokers, as reported in a study.

Adding interferon beta-1a to remdesivir did not hasten time to recovery among adults hospitalized with COVID-19, according to results of the phase III ACTT*-3 trial.

Among patients with systemic sclerosis-interstitial lung disease (SSc-ILD), radiographic progression of ILD over time is predictive of elevated long-term mortality, as shown in a study.

A large prospective, observational study has suggested that while individuals with a history of high-risk allergy may have an increased risk of allergic reactions following receipt of a messenger RNA (mRNA) COVID-19 vaccine, they are still able to receive both vaccine doses.

The combination of carbocisteine, gingko leaf extract, and milrinone yields significant clinical improvement in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), a recent study has found. In turn, this treatment regimen also leads to better patient quality of life.

A short-term treatment regimen based on high-dose gatifloxacin appears to be effective against multidrug- or rifampicin-resistant tuberculosis (TB) but at the cost of increased severe adverse drug reactions, as shown in a study.

Short-course nonmacrolide therapy in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) appears to have no significant effect on outcomes including mortality, progression to ventilation, readmission rate, or prevalence of adverse drug events, a study has shown.